SG11202108607QA - Crystalline forms of a jak2 inhibitor - Google Patents
Crystalline forms of a jak2 inhibitorInfo
- Publication number
- SG11202108607QA SG11202108607QA SG11202108607QA SG11202108607QA SG11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA
- Authority
- SG
- Singapore
- Prior art keywords
- crystalline forms
- jak2 inhibitor
- jak2
- inhibitor
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1902018A FR3092581A1 (fr) | 2019-02-12 | 2019-02-12 | Formes cristallines d'un inhibiteur de jak2 |
| PCT/US2020/017764 WO2020167844A1 (en) | 2019-02-12 | 2020-02-11 | Crystalline forms of a jak2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108607QA true SG11202108607QA (en) | 2021-09-29 |
Family
ID=68281482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108607QA SG11202108607QA (en) | 2019-02-12 | 2020-02-11 | Crystalline forms of a jak2 inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220332706A1 (pt) |
| EP (1) | EP3927704A4 (pt) |
| JP (1) | JP2022520083A (pt) |
| KR (1) | KR20210148110A (pt) |
| CN (1) | CN114026088A (pt) |
| AU (1) | AU2020221796A1 (pt) |
| BR (1) | BR112021015318A2 (pt) |
| EA (1) | EA202192237A1 (pt) |
| FR (1) | FR3092581A1 (pt) |
| IL (1) | IL285427A (pt) |
| MX (1) | MX2021009423A (pt) |
| SG (1) | SG11202108607QA (pt) |
| WO (1) | WO2020167844A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220031699A1 (en) | 2018-09-25 | 2022-02-03 | Impact Biomedicines, Inc. | Methods of treating myeloproliferative disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122021011788B1 (pt) * | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| TW201316989A (zh) * | 2011-07-21 | 2013-05-01 | Sanofi Sa | 用於治療真性多血症及原發性血小板過多症之組合物及方法 |
| MX2019007434A (es) * | 2016-12-21 | 2019-08-16 | Biotheryx Inc | Derivados de tienopirrol para uso en seleccion como diana de proteinas, composiciones, metodos y usos de los mismos. |
-
2019
- 2019-02-12 FR FR1902018A patent/FR3092581A1/fr active Pending
-
2020
- 2020-02-11 EP EP20756422.0A patent/EP3927704A4/en active Pending
- 2020-02-11 US US17/430,148 patent/US20220332706A1/en active Pending
- 2020-02-11 BR BR112021015318-7A patent/BR112021015318A2/pt unknown
- 2020-02-11 CN CN202080027762.4A patent/CN114026088A/zh active Pending
- 2020-02-11 KR KR1020217029156A patent/KR20210148110A/ko unknown
- 2020-02-11 MX MX2021009423A patent/MX2021009423A/es unknown
- 2020-02-11 SG SG11202108607QA patent/SG11202108607QA/en unknown
- 2020-02-11 WO PCT/US2020/017764 patent/WO2020167844A1/en unknown
- 2020-02-11 AU AU2020221796A patent/AU2020221796A1/en active Pending
- 2020-02-11 JP JP2021547092A patent/JP2022520083A/ja active Pending
- 2020-02-11 EA EA202192237A patent/EA202192237A1/ru unknown
-
2021
- 2021-08-06 IL IL285427A patent/IL285427A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL285427A (en) | 2021-09-30 |
| BR112021015318A2 (pt) | 2021-10-05 |
| EP3927704A4 (en) | 2022-12-28 |
| WO2020167844A1 (en) | 2020-08-20 |
| FR3092581A1 (fr) | 2020-08-14 |
| CN114026088A (zh) | 2022-02-08 |
| US20220332706A1 (en) | 2022-10-20 |
| JP2022520083A (ja) | 2022-03-28 |
| MX2021009423A (es) | 2021-11-17 |
| KR20210148110A (ko) | 2021-12-07 |
| AU2020221796A1 (en) | 2021-08-12 |
| EP3927704A1 (en) | 2021-12-29 |
| EA202192237A1 (ru) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287668A (en) | Crystalline forms of btk inhibitor | |
| EP3619208C0 (en) | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | |
| EP3923948A4 (en) | CRYSTALLINE SHAPES OF A JAK2 INHIBITOR | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| HUE064943T2 (hu) | Szubsztituált tiazolidin vegyület alkalmazása nitrifikációs inhibitorként | |
| IL282454A (en) | Crystalline salts of plasma kallikrein inhibitor | |
| IL287630A (en) | Solid forms of glyt1 inhibitor | |
| IL284226A (en) | Crystal structures of a TGFB inhibitor | |
| IL290087A (en) | inhibitory substances | |
| GB202004960D0 (en) | Inhibitor compounds | |
| GB202008201D0 (en) | Inhibitor compounds | |
| GB201914860D0 (en) | Inhibitor compounds | |
| IL285427A (en) | Crystal forms of jak2 inhibitor | |
| FI3891156T3 (fi) | Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia | |
| SG11202107225SA (en) | Crystalline form of a cdk inhibitor | |
| IL279953A (en) | Crystal forms of LTA4H inhibitor | |
| IL285493A (en) | Crystalline forms of rsk inhibitor | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| IL292847A (en) | Crystalline forms of magl inhibitor | |
| IL284222A (en) | Macrocrystalline forms of the PAR4 inhibitor | |
| IL284564A (en) | Polymorphic forms of a modified quinoline-type bridged piperidine compound | |
| GB201915908D0 (en) | Crystalline forms of entrectinib | |
| GB202107325D0 (en) | Inhibitor compounds | |
| GB202104781D0 (en) | Inhibitor compounds |